



WOMEN'S CANCER INITIATIVE  
TATA MEMORIAL HOSPITAL

# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

**18<sup>th</sup>-19<sup>th</sup> DEC, 2021**  
**SATURDAY & SUNDAY**



Organised by : Gynecologic Oncology  
Disease Management Group,  
Tata Memorial Centre, Mumbai

Click on the link below for registration

<https://www.riveroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riveroute**

Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

Dear Friends and Colleagues,

Women's Cancer Initiative-Tata Memorial Hospital invites you for the **"Year In Review in Gynecological Cancers"**. This meeting will be held on a virtual platform on **18<sup>th</sup> and 19<sup>th</sup> December 2021**.

The pandemic has slowed down research, in spite of this many clinical, translational and basic science studies in the field of gynecological oncology were published this year. Data to be discussed at the YIR 2021 meeting has been chosen from major gynecological cancer meetings and noteworthy publications from peer reviewed journals, likely to make an impact on our daily clinical practice.

Please find below the registration link for the meeting. We request you to popularise this link amongst your colleagues.

**<https://www.riverroute.in/wcigynyir2021>**

We look forward to your participation in YIR 2021.

With best wishes



**Dr. Amita Maheshwari**  
Organising Chairperson



**Dr. Kedar Deodhar**  
Convener, Gynecologic Oncology  
Disease Management Group



**Dr. Biswajit Dash**  
Organising Secretary



**Dr. Sushmita Rath**  
Organising Secretary

Click on the link below for registration

**<https://www.riverroute.in/wcigynyir2021>**

Virtual Webinar Managed by

**riverroute**  
Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 1

Dec, 18 2021, Saturday | 4.00 - 8.00 pm

### Scientific Program

04.00 pm - 04.05 pm ● Welcome Address

04.05 pm - 04.10 pm ● Overview of the Programme by Organising Chairperson

#### Session I: OVARIAN CANCER

04.10 pm - 04.30 pm ● PARP Inhibitors

- i. Prevalence of BRCA1 and BRCA2 Mutations Among Patients With Ovarian, Primary Peritoneal, and Fallopian Tube Cancer in India: A Multicenter Cross-Sectional Study.  
Gupta S. et al JCO Glob Oncol. 2021 Jun;7:849-861.
- ii. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.  
Banerjee S. et al Lancet Oncol. 2021 Dec;22(12):1721-1731.
- iii. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.  
Poveda A. et al Lancet Oncol. 2021 May;22(5):620-631.
- iv. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).  
Kwan T. et al Journal of Clinical Oncology 39, no. 15\_suppl (May 20, 2021) 5537-5537
- v. Rucaparib vs. chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study.  
Kristeleit R. et al, presented at: ESMO Gynaecological Cancers Virtual Congress; June 25-26, 2021.

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**  
Leaders in Streaming Modules



WOMEN'S CANCER INITIATIVE  
TATA MEMORIAL HOSPITAL



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 1

Dec, 18 2021, Saturday | 4.00 - 8.00 pm

### Scientific Program

- vi. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.  
Mirza MR. et al *Gynecol Oncol.* 2020 Nov;159(2):442-448.
- vii. Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: A multicenter, randomized, double-blind, placebo-controlled, phase III trial.  
Li N. et al *Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer.* Abstract 11557.  
Presented March 25, 2021.
- viii. PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.  
Agarwal A. et al *JCO Glob Oncol.* 2021 Apr;7:506-511.
- ix. Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.  
Martin JE. et al *Ann Oncol.* 2021 Aug;32(8):1046-1048.
- x. PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials.  
Morice PM et al. *Ann Oncol.* 2021 Aug;32(8):1048-1050.
- xi. Maintenance olaparib rechallenge in patients with ovarian carcinoma previously treated with a PARP inhibitor: Phase IIIb OReO/ENGOT Ov-38 trial.  
Pujade-Lauraine E et al *Annals of Oncology* (2021) 32 (suppl\_5): S1283-S1346. 10.1016

04.30 pm - 04.35 pm ●

#### Primary Debulking Surgery Versus NACT

- i. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850)  
Fagotti A. et al. *Int J Gynecol Cancer* 2020;30:1657-1664.

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**  
\* Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 1

Dec, 18 2021, Saturday | 4.00 - 8.00 pm

### Scientific Program

**04.35 pm - 04.40 pm** ● **HIPEC at secondary cytoreductive surgery**  
i. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.  
Zivanovic O et al. J Clin Oncol. 2021 Aug 10;39(23):2594-2604.

**04.40 pm - 05.20 pm** ● **Panel Discussion: OVARIAN CANCER**

**05.20 pm - 05.30 pm** ● **Concluding Remarks**

**05.30 pm - 05.50 pm** ● **Debate: Is there a role of secondary cytoreductive surgery in platinum sensitive relapsed ovarian cancer?**

**Rebuttal - 2 mins (1 min each)**

**Concluding Remarks**

**05.50 pm - 06.05 pm** **INAUGURATION**

### SESSION II: ENDOMETRIAL CANCER

**06.05 pm - 06.15 pm** ● **ESGO/ESTRO/ESP and NCCN Guidelines - What is new?**

**06.15 pm - 06.20 pm** ● **Minimally Invasive Surgery and Tumour Spill**  
i. Intraoperative Tumor Spill during Minimally Invasive Hysterectomy for Endometrial Cancer: A Survey Study.  
Chang-Patel E. et al AAGL 2021; Virtual Poster 5497.

**06.20 pm - 06.25 pm** ● **Sentinel Lymph Node Biopsy in Endometrial Cancer**

i. Assessment of Sentinel Lymph Node Biopsy vs Lymphadenectomy for Intermediate- and High-Grade Endometrial Cancer Staging.

Cusimano MC et al JAMA Surg. 2021 Feb 1;156(2):157-164

**06.25 pm - 06.30 pm** ii. Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.

Marchocki Z et al Am J Obstet Gynecol. 2021 Oct; 225(4): 367.e1-367.e39.

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules





# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 1

Dec, 18-2021, Saturday | 4.00 - 8.00 pm

### Scientific Program

06.30 pm - 06.35 pm ●

#### Adjuvant Therapy and Its Complications

- A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women with Stage IIIC Endometrial Cancer.  
*Hathout L et al Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1423-1431.*

06.35 pm - 06.43 pm

- Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

*Post CCB et al Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986. doi: 10.1016/j.ijrobp.2020.10.030.*

- Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy.

*Wortman BG et al Int J Radiat Oncol Biol Phys. 2021 Oct 2;S0360-3016(21)02846-7*

06.43 pm - 06.50 pm ●

#### Targeted Therapy

- A multicentre, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs. treatment of physician's choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775.

*Makker V et al International Journal of Gynecologic Cancer 2021; 31:A4-A5.*

- Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.

*Dominique Berton et al Journal of Clinical Oncology 39, no. 15\_suppl (May 20, 2021) 2564-2564al*

06.50 pm - 07.40 pm ●

#### Panel Discussion: ENDOMETRIAL CANCER

07:40 pm - 07:50 pm ●

#### Concluding Remarks

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

### Scientific Program

#### SESSION III: CERVICAL CANCER

10.00 am - 10.05 am

##### ● Conservative Surgery for low-risk early stage cervical cancer

- i. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.  
Schmeler KM. et al *Int J Gynecol Cancer*. 2021 Oct;31(10):1317-1325. doi: 10.1136/ijgc-2021-002921

10.05 am - 10.30 am

##### ● Radiotherapy

10.05 am - 10.10 am

- i. Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.

Levinson K. et al *Gynecol Oncol*. 2021 Sep;162(3):532-538

10.10 am - 10.15 am

- ii. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.

Chopra S J. *Clin Oncol*. 2021 Nov 20;39(33):3682-3692.

10.15 am - 10.20 am

- iii. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.

Potter R. et al *Lancet Oncol*. 2021 Apr;22(4):538-547.

10.20 am - 10.25 am

- iv. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.

Huang H. et al *JAMA Oncol*. 2021 Mar 1;7(3):361-369.

10.25 am - 10.30 am

- v. Sequential Chemotherapy for Early-Stage, Post-Radical Hysterectomy Cervical Cancer: Are the STARS Aligned?

Randall LM. et al *JAMA Oncol*. 2021 Mar 1;7(3):353-354.

10.30 am - 10.45 am

##### ● Targeted therapy in advanced cervical cancer

10.30 am - 10.35 am

- i. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.

Coleman RL. et al *Lancet Oncol*. 2021 May;22(5):609-619.

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

### Scientific Program

10.35 am - 10.40 am

- ii. Adjuvant chemotherapy following chemo radiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, and NRG 0274)  
Mileshkin LR. et al Journal of Clinical Oncology 2021 39:18\_suppl, LBA3-LBA3.

10.40 am - 10.45 am

- iii. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.  
Colombo N et al, N Engl J Med. 2021 Nov 11;385(20):1856-1867.

10.45 am - 10.50 am

- **Preventive oncology**
  - i. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study  
Basu P et al, Lancet Oncol. 2021 Nov;22(11):1518-1529.

10.50 am - 11.40 am

- **Panel Discussion: CERVICAL CANCER**

11.40 am - 11.50 am

- **Concluding Remarks**

#### SESSION IV: RAPID-FIRE

11.50 am - 12.00 pm

- **What is new in Gynec Oncopathology- An Overview of WHO Blue book 2020**

12.00 pm - 12.20 pm

- **Ovarian Cancer**
  - i. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.  
Morgan RD. et al Lancet Oncol. 2021 Feb;22(2):277-288.
  - ii. Cisplatin and paclitaxel is associated with improved progression-free survival compared to cisplatin alone during interval debulking surgery with HIPEC in women with advanced epithelial ovarian cancer  
Chambers LM. et al SGO 2021; Abstract 101.

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**

Leaders in Streaming Modules





# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

### Scientific Program

- iii. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.  
*Falandry C. et al, JAMA Oncol. 2021 Jun 1;7(6):853-861.*
- iv. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).  
*Moore KN et al, J Clin Oncol. 2021 Jun 10;39(17):1842-1855.*
- v. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.  
*Pujade-Lauraine E. et al, Lancet Oncol. 2021 Jul;22(7):1034-1046*
- vi. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).  
*Hamanishi J. et al, J Clin Oncol. 2021 Nov 20;39(33):3671-3681*
- vii. Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta-analysis.  
*Beebejaun Y et al, Fertil Steril. 2021 Jul;116(1):198-207*
- viii. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study.  
*Schrijver LH. et al, Am J Obstet Gynecol. 2021 Jul;225(1):51.e1-51.e17.*
- ix. Association of Germline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data.  
*Turan V. et al, J Clin Oncol. 2021 Jun 20;39(18):2016-2024.*
- x. Image-Guided Percutaneous Thermal Ablation of Oligometastatic Ovarian and Non-Ovarian Gynecologic Tumors. J Vasc Interv Radiol  
*Yuan F et al, 2021 May;32(5):729-738.*

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**<sup>®</sup>

\* Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

### Scientific Program

12.20 pm - 12.35 pm

#### Cervical Cancer

- i. Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study.  
*Bowden SJ. et al, Lancet Oncol. 2021 Apr;22(4):548-557.*
- ii. Machine learning applications in radiation oncology.  
*Field M et al Phys Imaging Radiat Oncol. 2021 Jun 24;19:13-24.*
- iii. Development and clinical validation of Knowledge-based planning for Volumetric Modulated Arc Therapy of cervical cancer including pelvic and para aortic fields.  
*Swamidas J et al, Phys Imaging Radiat Oncol. 2021 May 26;18:61-67.*
- iv. Single Application Multifractionated Image Guided Adaptive High-Dose-Rate Brachytherapy for Cervical Cancer: Dosimetric and Clinical Outcomes.  
*Mahantshetty U et al, Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):826-834.*
- v. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD)  
*Macchia G. et al International Journal of Gynecologic Cancer 2021;31:A52-A53.*
- vi. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network.  
*Chopra S et al, Radiother Oncol. 2021 Feb;155:151-159.*
- vii. Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review.  
*Yegya-Raman N, Gynecol Oncol. 2020 Nov;159(2):573-580*
- viii. Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India.  
*Singhal A et al Adv Radiat Oncol. 2021 Nov-Dec;6(6):100725.*
- ix. Prophylactic Extended-Field Irradiation in Patients With Cervical Cancer: A Literature Review.  
*Wang W. et al, Front Oncol. 2020 Oct 2;10:579410.*
- x. Uterine perforation during brachytherapy for cervical cancer: Complications, outcomes, and best practices for forward treatment planning and management.  
*Small W Jr et al, Brachytherapy. 2021 May-Jun;20(3):557-564.*

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**  
\* Leaders in Streaming Modules



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

### Scientific Program

12.35 pm - 12.45 pm

#### ● Endometrial Cancer

- Prospective Cohort Study of Pre- and Post-Diagnosis Obesity and Endometrial Cancer Survival.  
*Kokts-Porietis RL et al, J Natl Cancer Inst. 2021 Oct 1:djab197.*
- Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial.  
*Janda M et al. Gynecol Oncol. 2021 Apr;161(1):143-151.*
- Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.  
*Westin SN. et al, Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15.*
- Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis.  
*McAlpine JN. et al, Cancer. 2021 Jul 15;127(14):2409-2422.*
- Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.  
*Liu JF et al, J Clin Oncol. 2021 May 10;39(14):1531-1539.*
- Association Between Adjuvant Therapy and Survival in Stage II-III Endometrial Cancer: Influence of Malignant Peritoneal Cytology.  
*Matsuo K et al Ann Surg Oncol. 2021 Nov;28(12):7591-7603*

12.45 pm - 12.55 pm

#### ● Miscellaneous (GTN/Vulvar Cancer)

- Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.  
*Braga A. et al, Lancet Oncol. 2021 Aug;22(8):1188-1198.*
- FIGO staging for carcinoma of the vulva: 2021 revision.  
*Olawaiye AB et al, Int J Gynaecol Obstet. 2021 Oct;155(1):43-47.*
- Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II.  
*Oonk MHM. et al, J Clin Oncol. 2021 Nov 10;39(32):3623-3632.*

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**  
\* Leaders in Streaming Modules



WOMEN'S CANCER INITIATIVE  
TATA MEMORIAL HOSPITAL



# YEAR IN REVIEW IN GYNECOLOGICAL CANCERS

18<sup>th</sup>-19<sup>th</sup> DEC, 2021  
SATURDAY & SUNDAY

## DAY 2

Dec, 19-2021, Sunday | 10.00 am - 1.30 pm

### Scientific Program

- iv. Pembrolizumab for Vulvar Squamous Cell Carcinoma: Results From the Phase 2 KEYNOTE-158 Study. Frommer RS, et al Abstract presented at: Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women's Cancer; March 19-21, 2021; Virtual. Abstract 11603.

12.55 pm - 01.05 pm ● **Concluding Remarks**

01.05 pm - 01.10 pm ● **Vote of Thanks**

For virtual conference and cme management

**Please Contact**

**riverroute**<sup>®</sup>

■ Leaders in Streaming Modules

**Amey Kadam**

**rrcg.amey@gmail.com | +91 98212 41572**

Click on the link below for registration

<https://www.riverroute.in/wcigynyir2021>

Virtual Webinar Managed by

**riverroute**<sup>®</sup>

■ Leaders in Streaming Modules